GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 101 filers reported holding GRITSTONE ONCOLOGY INC in Q1 2021. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $238,426 | -32.8% | 138,620 | -23.8% | 0.00% | 0.0% |
Q2 2023 | $354,771 | -31.7% | 181,934 | -2.7% | 0.00% | -50.0% |
Q1 2023 | $519,677 | -19.4% | 186,934 | 0.0% | 0.00% | -33.3% |
Q4 2022 | $644,923 | +34.4% | 186,934 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $480,000 | +42.9% | 186,934 | +34.5% | 0.00% | +50.0% |
Q2 2022 | $336,000 | -25.7% | 138,947 | +26.5% | 0.00% | -33.3% |
Q1 2022 | $452,000 | -56.3% | 109,800 | +36.4% | 0.00% | -57.1% |
Q4 2021 | $1,035,000 | +73.9% | 80,500 | +46.1% | 0.01% | +40.0% |
Q3 2021 | $595,000 | +202.0% | 55,100 | +155.1% | 0.01% | +150.0% |
Q2 2021 | $197,000 | +99.0% | 21,600 | +105.7% | 0.00% | +100.0% |
Q1 2021 | $99,000 | -66.9% | 10,500 | -86.2% | 0.00% | -75.0% |
Q4 2020 | $299,000 | -3.2% | 75,884 | -33.9% | 0.00% | -20.0% |
Q3 2020 | $309,000 | -59.4% | 114,884 | -1.2% | 0.01% | -61.5% |
Q2 2020 | $761,000 | +28.8% | 116,254 | +11.9% | 0.01% | 0.0% |
Q1 2020 | $591,000 | +79.6% | 103,854 | +156.7% | 0.01% | +160.0% |
Q4 2019 | $329,000 | – | 40,454 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |